Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog)

E. J. Lee, K. R. Kim, S. K. Lim, H. C. Lee, D. I. Kim, S. H. Kim, K. B. Huh

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

We present a 55-year-old female with a thyrotropin (TSH)-secreting pituitary adenoma who had been treated with somatostatin analog octreotide acetate (SMS 201-995) for 4 months. Subcutaneous injection of 100 μg octreotide acetate twice daily resulted in significant reduction of the TSH, thyroid hormone, and tumor size. During the treatment, there was no evidence of any side effects. We may conclude that octreotide acetate administration is an effective treatment in patients with TSH-secreting pituitary adenoma for suppressing TSH hypersecretion and reducing the size of the tumor.

Original languageEnglish
Pages (from-to)109-112
Number of pages4
JournalEuropean Journal of Endocrinology
Volume131
Issue number1
DOIs
Publication statusPublished - 1994

All Science Journal Classification (ASJC) codes

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint Dive into the research topics of 'Reduction in size of a thyrotropin-secreting pituitary adenoma treated with octreotide acetate (somatostatin analog)'. Together they form a unique fingerprint.

  • Cite this